Literature DB >> 20618171

The phosphate regulating hormone fibroblast growth factor-23.

R Marsell1, K B Jonsson.   

Abstract

Over the last decade, the regulation of phosphate (Pi) homeostasis has been under intense investigation. By utilizing modern biochemical and genetic tools, the pathophysiological mechanisms behind several known hereditary and acquired hypo- and hyperphosphatemic diseases have been clarified. The results of these efforts have opened new insights into the causes of Pi dysregulation and hereby also the physiological mechanisms determining Pi homeostasis. Although several potential Pi-regulating proteins have been discovered and investigated, current data strongly argues for fibroblast growth factor-23 (FGF23), a hormonal factor produced in bone, as a particularly important regulator of Pi homeostasis. In this article, we review the discovery of the FGF23 protein, as well as its biochemistry, localization of production, receptor specificity and mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20618171     DOI: 10.1111/j.1748-1716.2010.02163.x

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  12 in total

1.  A Novel Osteogenic Cell Line That Differentiates Into GFP-Tagged Osteocytes and Forms Mineral With a Bone-Like Lacunocanalicular Structure.

Authors:  Kun Wang; Lisa Le; Brad M Chun; LeAnn M Tiede-Lewis; Lora A Shiflett; Matthew Prideaux; Richard S Campos; Patricia A Veno; Yixia Xie; Vladimir Dusevich; Lynda F Bonewald; Sarah L Dallas
Journal:  J Bone Miner Res       Date:  2019-06-07       Impact factor: 6.741

2.  Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo.

Authors:  Stacey M Woo; Jennifer Rosser; Vladimir Dusevich; Ivo Kalajzic; Lynda F Bonewald
Journal:  J Bone Miner Res       Date:  2011-11       Impact factor: 6.741

3.  FGF23 Is Not Required to Regulate Fetal Phosphorus Metabolism but Exerts Effects Within 12 Hours After Birth.

Authors:  Yue Ma; Beth J Kirby; Nicholas A Fairbridge; Andrew C Karaplis; Beate Lanske; Christopher S Kovacs
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

4.  Regulation of mineral metabolism by lithium.

Authors:  Hajar Fakhri; Ganesh Pathare; Abul Fajol; Bingbing Zhang; Thomas Bock; Reinhard Kandolf; Erwin Schleicher; Jürg Biber; Michael Föller; Undine E Lang; Florian Lang
Journal:  Pflugers Arch       Date:  2013-09-07       Impact factor: 3.657

5.  Neither absence nor excess of FGF23 disturbs murine fetal-placental phosphorus homeostasis or prenatal skeletal development and mineralization.

Authors:  Yue Ma; Manoharee Samaraweera; Sandra Cooke-Hubley; Beth J Kirby; Andrew C Karaplis; Beate Lanske; Christopher S Kovacs
Journal:  Endocrinology       Date:  2014-03-06       Impact factor: 4.736

6.  trpm7 regulation of in vivo cation homeostasis and kidney function involves stanniocalcin 1 and fgf23.

Authors:  Michael R Elizondo; Erine H Budi; David M Parichy
Journal:  Endocrinology       Date:  2010-09-29       Impact factor: 4.736

7.  Associations between circulating 1,25(OH)₂D concentration and odds of metachronous colorectal adenoma.

Authors:  Elizabeth A Hibler; Christine L Sardo Molmenti; Peter Lance; Peter W Jurutka; Elizabeth T Jacobs
Journal:  Cancer Causes Control       Date:  2014-04-16       Impact factor: 2.506

8.  Circulating fibroblast growth factor-23 is associated with increased risk for metachronous colorectal adenoma.

Authors:  Elizabeth Jacobs; Maria Elena Martinez; Julie Buckmeier; Peter Lance; Melissa May; Peter Jurutka
Journal:  J Carcinog       Date:  2011-02-12

9.  Murine Fetal Serum Phosphorus is Set Independent of FGF23 and PTH, Except in the Presence of Maternal Phosphate Loading.

Authors:  K Berit Sellars; Brittany A Ryan; Sarah A Hartery; Beth J Kirby; Christopher S Kovacs
Journal:  Endocrinology       Date:  2021-01-01       Impact factor: 5.051

10.  Impact of lithium treatment on FGF-23 serum concentrations in depressive patients.

Authors:  Hajar Fakhri; Roland Ricken; Mazda Adli; Abul Fajol; Marc Walter; Michael Föller; Florian Lang; Undine E Lang; Claudia Lange
Journal:  J Clin Psychopharmacol       Date:  2014-12       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.